about
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyPharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell CarcinomaA phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumoursA phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 studyA phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRNivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortTumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerAuthor Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersPhase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsRamucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trialMulticenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsNivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsEarly-phase clinical drug development of novel agents: a changing paradigmCorrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung CancerNew designs in early clinical drug developmentSafety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialIncreased vulnerability of clinical research units during the COVID-19 crisis and their protection
P50
Q34658293-C3EA4B95-6FFA-40BC-91C3-F4FDF685F9ADQ35289038-D90BA7D4-E5C2-4FF8-AB4B-D86E8B967FBCQ38199328-4B1238F9-707D-4285-BE6C-3FDFDC148B3CQ38375426-B057D53A-64FD-49CD-A1D0-A7D638E77D9BQ38983310-EB9ED026-D53B-4F3F-9D82-82023988D076Q39015140-467F9CA9-8EE1-403A-8910-265AA807BEB6Q42470208-7C8F6456-F5FD-4EF0-AFD1-720E5AC59D18Q45825472-1C059856-E4A3-4301-8B6D-81B46A70D1AAQ45907302-53BFBB78-584F-420B-9950-CF98AA30567EQ47204017-32602395-509E-480F-A3F8-BE4F58C61BFAQ50115014-4B7069B4-CF57-453C-AB9A-158F6E89C49FQ56889715-89B36518-458B-41A3-9CC9-D56F8CBCAF36Q57064895-B18DFC67-4301-4188-A1DC-BDB5BD066D10Q61443285-B949FDEF-A11A-42B6-B3F3-8ABC0700E5FFQ89833034-8CEC6912-5C79-4DE1-BC80-372E2D525F14Q89837815-6FEF751E-B432-4BDA-8435-E4FA67B5B75DQ90068660-9DB00B84-615A-4A4F-B329-5FB51DD9CDC6Q90440015-57C1D06C-473D-4069-8A18-A628DF76D580Q90822787-7D34A393-32F3-49FE-A324-9AAC9B7BD3B7Q91503324-19C05499-A424-4984-81AD-48E1EA0A07EFQ91521167-CFA05D85-28E2-4FC1-9ADC-E77D42AF5A4EQ91632377-CC4B9051-883B-434E-8423-3753BE03948FQ91851580-7AAE61F6-2C61-452B-B772-E53714325D45Q92020220-4F002813-DE5A-4268-A750-4AA7EE948073Q92112847-72F8649F-8A0F-48AD-A5A4-A54443A0FE6CQ92202815-E4417D19-5A8C-42A7-AE1E-B642209966E7Q92374664-F6ACCFE6-81A9-4F65-AE41-36E48BE12322Q92387102-925655E0-3515-44F7-9BA0-B295B83DF60BQ92890493-93718117-1A6E-4015-ABE3-BC01FCC6F723Q93121862-96F55A1D-5E23-41AF-BF0F-2EEDB1FC0C60Q96584146-269712C6-C3E5-4B3E-92FF-DB34728E8E2D
P50
description
researcher
@en
name
Emiliano Calvo
@en
type
label
Emiliano Calvo
@en
prefLabel
Emiliano Calvo
@en
P31
P496
0000-0003-4921-829X